Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib
Lung cancer (Amsterdam, Netherlands), 2019.
Acquired resistanceConcurrent genomic landscapeNext-generation sequencingNon-small cell lung cancerOsimertinibMore(1+)
Known EGFR-dependent resistant mutations and activation of alternative pathways were identified in 44 % of all the patients with great heterogeneity. Gain-of-function mutations of CTNNB1 were highly enriched in our cohort. Some other putative resistance mechanisms to osimertinib, such as the recurrent EGFR V834 L mutation, were also ident...More
Full Text (Upload PDF)
PPT (Upload PPT)